14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
NVCT vs CGEN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Nuvectis Pharma, Inc. (NVCT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NVCT carries a Unified Composite Score of 53.4/100 (HOLD) at $19.20 (N/M Forward P/E, 0.0% operating margin), whereas CGEN carries 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin).
Composite vs. Pillar Nuance: While NVCT currently prints a higher short-term Unified Composite Score (53.4/100 HOLD vs. CGEN 47.1/100 HOLD), CGEN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (41.3% vs. 0.0% operating margin) and revenue trajectory (+102.1% vs. +0.0% YoY).
Technical & Structure Timing Caution: NVCT is currently in a Breakdown options structure phase (RSI 46.0); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVCT vs CGEN. Trailing 12-month operating profitability (NVCT 0.0% vs CGEN 41.3%) and valuation multiples (NVCT N/M vs CGEN 12.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $657.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
CGEN Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $193.2M market capitalization and 41.3% operating margin.
OpEx & R&D Reinvestment44.9% of Rev ($34M)
90D Engineering Disclosures0 Published
Investor FAQ NVCT vs CGEN Key Questions & Quantitative Answers
As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Nuvectis Pharma, Inc. (NVCT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NVCT carries a Unified Composite Score of 53.4/100 (HOLD) at $19.20 (N/M Forward P/E, 0.0% operating margin), whereas CGEN carries 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin). Composite vs. Pillar Nuance: While NVCT currently prints a higher short-term Unified Composite Score (53.4/100 HOLD vs. CGEN 47.1/100 HOLD), CGEN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (41.3% vs. 0.0% operating margin) and revenue trajectory (+102.1% vs. +0.0% YoY). Technical & Structure Timing Caution: NVCT is currently in a Breakdown options structure phase (RSI 46.0); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CGEN leads the Growth & Scale pillar: NVCT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CGEN at +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin). On trailing 12-month operating scale, NVCT generates N/A in USD-normalized revenue versus $76M for CGEN. In operating R&D and SG&A reinvestment, NVCT deploys N/A (0 90-day corporate R&D disclosures) versus 44.9% of Rev ($34M) (0 disclosures) for CGEN.
CGEN screens cheaper on headline valuation multiples. NVCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CGEN trades at 12.4x Forward P/E, 5.2x Trailing P/E, 1.29x PEG, and 2.5x EV/Revenue (41.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVCT (-67.0% ROE) versus CGEN (57.2% ROE) capital efficiency.
In options market volatility and institutional positioning, NVCT carries 142.5% implied volatility (22nd %ile, Compressed (<25th %ile)), a 6.68x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.70β · 82% Vol realized risk). By comparison, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.